Compare Recursion Pharmaceuticals Inc (RXRX) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Shell PLC — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Shell PLC trades at $95.6 (market cap $271.34B). The key difference: Shell PLC is far larger — about 145.9× Recursion Pharmaceuticals Inc's market cap, and Shell PLC pays a 3.28% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SHEL | |
|---|---|---|
Market Cap | $1.86B | $271.34B |
Sector | Health | Energy |
52-Week High | $6.79 | $95.60 |
52-Week Low | $2.84 | $70.31 |
Enterprise Value | $1.38B | $313.04B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Shell (SHEL) trades at $95.32, up 2.55% with strong bullish momentum as crude oil prices rally. The stock shows robust fundamentals with a P/E of 10.54 and net income margin of 8.76%, while recent Q2 2026 earnings beat expectations. Technical indicators signal bullish sentiment with the price near resistance at $96. Recent acquisitions including ARC Resources and strategic partnerships with BP expand Shell's deepwater footprint, driving growth prospects.
Outlook remains positive with analyst consensus price target of $101 (6% upside), supported by 61.5% buy ratings. Key risks include oil price volatility and geopolitical tensions, but strong cash flow generation and strategic expansions position SHEL for sustained growth. The current valuation appears attractive relative to earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
